Owens Daniel E.
Known title: Chief HR OfficerCIK: 0001858105
Associated companies
Transaction History
| TMCI | ▲ Buy | Option Exercise | 6,250 | $44K | 3/15/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 6,250 | $143K | 3/15/2023 | View on chart |
| TMCI | ▲ Buy | Grant | 20,625 | $0 | 3/10/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 411 | $10K | 3/9/2023 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 3,750 | $26K | 12/2/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 3,750 | $94K | 12/2/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,875 | $32K | 12/2/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,875 | $47K | 12/2/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 6,250 | $44K | 11/15/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 6,250 | $127K | 11/15/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,500 | $30K | 9/2/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,500 | $11K | 9/2/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,000 | $7K | 9/1/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,000 | $20K | 9/1/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,500 | $30K | 8/15/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,500 | $11K | 8/15/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,000 | $17K | 8/1/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,000 | $7K | 8/1/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,000 | $7K | 7/5/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,000 | $15K | 7/5/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,000 | $17K | 6/1/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,000 | $7K | 6/1/2022 | View on chart |
| TMCI | ▲ Buy | Option Exercise | 1,000 | $7K | 5/9/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,000 | $16K | 5/9/2022 | View on chart |
| TMCI | ▲ Buy | Grant | 6,700 | $0 | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.